Entering its thirteenth year, the Anglonordic Life Science Conference XIII in London continues to grow and gave its audience the opportunity to meet 400 decision makers representing leading and upcoming R&D companies, international pharmaceuticals and investment firms.
This year’s event took place at a new location, 8 Northumberland Avenue, just a few steps from Trafalgar Square. The conference had a selected audience of 400 anglonordic region decision-makers from the fields of drug discovery, medtech, pharmaceuticals and investment firms. In total more than 60 European investment firms was expected to attend. The three guest countries, Belgium, Australia and Spain, also participated with a delegation of R&D companies and investment firms.
As in previous years, the conference was divided into five areas that have simultaneous activities; the main conference room 1, with a focus on biotech, the main conference room 2 with a focus on medtech, the one-to-one meeting area, the exhibiting area and the lounge area. Highlights of the programme included an update about the investment status in the medtech industry, the digital health investment landscape and latest news on European funding.